CD38 and hematopoietic and lymphoid cell neoplasm: We evaluated the ability of anti-CD38 antibodies to kill CD38+ hematologic cancer cell lines through ADCC, CDC, ADCP, and apoptosis induction using in vitro assays and inhibited CD38 enzymatic activity (Table 1).